Viral infections:

Indications for RUKOBIA:

In combination with other antiretroviral(s), for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.

Adult:

Swallow whole. 600mg twice daily.

Children:

Not established.

Contraindications:

Concomitant strong CYP3A4 inducers (eg, enzalutamide, carbamazepine, phenytoin, rifampin, mitotane, St. John's wort).

Warnings/Precautions:

History of QTc interval prolongation. Preexisting cardiac disease. Immune reconstitution syndrome. Monitor LFTs in those with hepatitis B and/or C coinfection. Elderly. Pregnancy. Nursing mothers: not recommended.

Pharmacologic Class:

HIV-1 gp120-directed attachment inhibitor.

Interactions:

See Contraindications. May be antagonized by strong CYP3A4 inducers. May potentiate HCV direct-acting antivirals (eg, grazoprevir, voxilaprevir), statins drugs (eg, rosuvastatin, atorvastatin, fluvastatin, pitavastatin, simvastatin), ethinyl estradiol. Caution when concomitant drugs with a known risk for Torsade de Pointes.

Adverse Reactions:

Nausea, diarrhea, headache, abdominal pain, dyspepsia, fatigue, rash, sleep disturbance; elevated transaminases.

Generic Availability:

NO

How Supplied:

Ext-rel tabs—60

Pricing for RUKOBIA

600mg tablet (Qty: 60)
Appx. price $7813
GoodRx